News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Astellas Gene Therapies
NEWS
JOBS
IN THE PRESS
NEWS
Business
San Francisco’s Audentes Appoints Three Execs Amidst Rumors of an IPO
September 29, 2015
·
3 min read
Deals
San Francisco’s Audentes Inks Deal to Buy Cardiogen Sciences
September 1, 2015
·
2 min read
Biotech Bay
San Francisco’s Audentes Therapeutics Rakes In $42.5 Million Series B
December 2, 2014
·
1 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Deals
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 19, 2019
July 19, 2019
·
2 min read
Deals
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 7, 2019
June 7, 2019
·
2 min read
Business
Audentes Therapeutics Announces Changes to Senior Management Team
May 29, 2019
·
5 min read
Biotech Bay
Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference
May 8, 2019
·
1 min read
Deals
Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 7, 2019
·
11 min read
Drug Development
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy
May 1, 2019
·
8 min read
Business
Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019
April 30, 2019
·
1 min read
Deals
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 26, 2019
April 26, 2019
·
2 min read
Business
Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility
April 23, 2019
·
4 min read
Drug Development
Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
April 15, 2019
·
8 min read
